Spotlight: Health Technology Assessment
Welcome to The Evidence Base Spotlight on the ‘Health Technology Assessment’.
Read selected coverage of various guidances and frameworks from HTA bodies around the world.
For more content on HTA, click here.
Europe
New OHE report on best practices for real-world evidence in reimbursement decision-making
Office of Health Economics issues new guidance on current best practices for the generation and use of real-world evidence in reimbursement decision-making.
Launch of NICE real-world evidence framework heralds a new era in health technology assessment in the UK
The eagerly anticipated NICE real-world evidence framework outlines how and when real-world-data can be used in submissions to NICE as well as clearly describing best-practices to improve the quality and transparency of real-world evidence studies.
Multistakeholder perspectives on Joint Clinical Assessment in Europe: opportunities and challenges for improving patient access to new treatments
The Regulation (EU) 2021/2282EN on health technology assessment (HTAR) came into effect in January 2022 and, when fully applied from January 2025, is set to transform HTA in Europe. To be implemented under this regulation, the Joint Clinical Assessment (JCA) process aims to streamline the assessment process of new medical treatments and devices across Europe with the ultimate goal of improving patient access to novel therapies.
North America
ICER white paper recommends health technology assessment strategies to improve health equity
ICER publishes their white paper proposing a series of recommendations and guidelines for health technology assessment to advance society’s ethical goal of improving health inequity related to racial, ethnic, and socioeconomic status.
CADTH joint final guidance on reporting real-world evidence studies in Canada
CADTH, in association with Health Canada and INESSS, has produced the final guidance for regulatory and health technology assessment agencies in Canada to advance the integration of real-world evidence in healthcare decision making.
Latin America
1st GetReal Institute Annual Conference: Deep dive into Session 5 – Experiences and challenges of using RWE for decision-making in Latin America
In Session 5 of the 1st GetReal Institute Annual Conference, the audience heard from experts about RWE for decision-making in Latin America, focusing on the regional uses and growing acceptability of RWE in the face of several issues such as fragmented healthcare systems and varying data quality.
Read more in our Expert Insight interviews and Editorials here:
Market access and HTA – a snapshot of recent developments with Sreeram Ramagopalan: April–June 2023
Read highlights from the first instalment of Sreeram Ramagopalan’s (Lane Clark & Peacock, UK) industry news round-up, which reviews recent developments in market access and health technology assessment (HTA), and is published bi-monthly in our partner journal, the Journal of Comparative Effectiveness Research.
RWE and HTA – a snapshot of recent developments with Sreeram Ramagopalan: March–May 2023
Read highlights from the latest instalment of Sreeram Ramagopalan’s (Lane Clark & Peacock, UK) industry news round-up, which discusses some of the latest developments regarding real-world evidence (RWE) in the context of health technology assessment (HTA) and is published bi-monthly in our partner journal, the Journal of Comparative Effectiveness Research.
For what it’s worth: the complex area of medicine value assessment
Egilman et al. recently investigated the therapeutic benefit of the most popular branded pharmaceuticals covered by Medicare in 2020, as determined by HTA bodies in Canada, France, and Germany. The authors concluded that many top prescribed drugs have low benefit ratings from these HTA agencies, and this information could be helpful for the future when Medicare are able to negotiate pricing as part of the Inflation Reduction Act.
Creating equity in healthcare decision making through real-world evidence: an interview with Grammati Sarri, Cytel
We speak with Grammati Sarri (Cytel, UK) to learn how RWE is being leveraged to ensure wider representativeness across diverse patient groups in health technology development and assessment.
Evaluating the quality of real-world evidence with a standardized assessment tool: an interview with Ashley Jaksa and Katsiaryna Bykov
To address the need to enhance the quality of RWE assessment, an ISPE-led group created an assessment tool to aid HTA bodies and payer decision makers in evaluating RWE studies.
Overcoming barriers to optimal use of RWE in HTA with a repository of evidence: an interview with Linda Murphy, Lumanity
In this interview, we speak with Linda Murphy (Lumanity) about a proposed new repository for RWD/RWE to learn about its creation, development and potential uses.
Emerging role of US healthcare data in global health technology assessment: a multistakeholder perspective
In this interview, Karen Facey (University of Edinburgh), Laurie Lambert (CADTH), Ashley Jaksa (Aetion), Joshua Ray (Roche) share some of the discussion points from the recent ISPOR 2023 Workshop “Can US Healthcare Data Inform HTAs in Other Parts of the World”.
Achieving patient-centered, equity-focused health technology assessment with the Innovation and Value Initiative: an interview with Jennifer Bright
We speak with Jennifer Bright, Chief Engagement and Strategy Officer at IVI about the institute and the work they are doing to achieve patient-centered, equity-focused HTA.
Health equity in health technology assessment: an interview with Melanie Whittington
Following a workshop at the recent ISPOR 2023 conference, we spoke with Melanie Whittington of ICER to learn more about the findings from the project and understand alternative methods that can be employed to assess the impact of a healthcare treatment on equity.
Health technology assessment of AI technologies: an interview with Rossella Di Bidino
In this interview, we learn from Rossella Di Bidino (Fondazione Policlinico Universitario Agostino Gemelli) about the current assessment of AI technologies and how HTA bodies need to adapt to evaluate such technologies.
Transferability of RWE methods and patient engagement practices in HTA from Western to Central and Eastern European countries
Bertalan Németh of the Syreon Research Institute discusses the ‘Transferability and dissemination’ work package from HTx, which has been tasked with understanding the transferability of knowledge and methods gained to Central and Eastern European countries, developing tactics for the dissemination any learnings and engaging patient representatives in HTA implementation.
Get in touch to discuss the opportunities available to share your expertise, contribute to this theme or to become a theme sponsor.
